Article
05 Jun 2025
Celltrion, Samsung Bioepis, And Organon Receive Interchangeability Designations For Adalimumab Biosimilars
RANKINGS
This author falls within the Top 20% for their listed topics and industry categories. Based on Mondaq users readership, this author is ranked as VERY POPULAR in United States
AUTHORS CONTENT
Article
20 Dec 2024
FDA Approves New Biologic Cancer Treatments
Article
12 Nov 2024
Daewoong And Celltrion To Market Denosumab Biosimilar In Korea
Article
26 Jul 2024
FDA Approves Samsung's Eculizumab Biosimilar
Article
17 May 2024
Alexion's Preliminary Injunction Motion Denied In Eculizumab BPCIA Litigation Against Samsung Bioepis
Article
15 Apr 2024
FDA Approves New Indication For AstraZeneca And Daiichi Sankyo's Cancer Drug ENHERTU
Article
18 Mar 2024
FDA Approves Sandoz Denosumab Biosimilars
Article
15 Mar 2024
Biocon Settles With Janssen, Securing U.S. Market Entry Date For Ustekinumab Biosimilar
Article
15 Mar 2024
Biocon Settles With Bayer And Regeneron, Securing Canada Market Entry Date For Aflibercept Biosimilar
Article
12 Feb 2024
Biosimilar Regulatory Updates